Literature DB >> 17921074

Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study.

Jung-Woo Bae1, Mi-Jeong Kim, Choon-Gon Jang, Seok-Yong Lee.   

Abstract

A simple and sensitive high performance liquid chromatography method using UV detection (HPLC-UV) for the determination of meloxicam in human plasma was developed and validated. After extraction with diethyl ether, the chromatographic separation of meloxicam was carried out using a reverse phase Sunfire C18 column (150 mm x 4.6mm, 5 microm) with a mobile phase of acetonitrile-20mM potassium hydrogen phosphate (40:60, v/v, pH 3.5) and UV detection at a wavelength of 355 nm. The flow rate of mobile phase was 1.2 ml/min and the retention time of meloxicam and internal standard, piroxicam, was found to be 11.6 and 6.3 min, respectively. The calibration curve was linear within the concentration range, 10-2400 ng/ml (r2>0.9999). The lower limit of quantification was 10 ng/ml. This method improved the sensitivity for the quantification of meloxicam in plasma using a HPLC-UV. The mean accuracy was 98-114%. The coefficient of variation (precision) in the intra- and inter-day validation was 1.6-4.3 and 2.4-7.3%, respectively. The pharmacokinetics of meloxicam was evaluated after administering an oral dose of 15 mg to 11 healthy Korean subjects. The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17921074     DOI: 10.1016/j.jchromb.2007.09.004

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  11 in total

1.  Determination of meloxicam using europium sensitized luminescence in the presence of co-luminescence reagents.

Authors:  Salma Muhamed Z Al-Kindy; Salim K Al-Habsy; Fakhr Eldin O Suliman; Haidar A J Al-Lawati
Journal:  J Fluoresc       Date:  2011-09-22       Impact factor: 2.217

2.  Optimization of photocatalytic degradation of meloxicam using titanium dioxide nanoparticles: application to pharmaceutical wastewater analysis, treatment, and cleaning validation.

Authors:  Ahmed H Nadim; Medhat A Al-Ghobashy; Marianne Nebsen; Mostafa A Shehata
Journal:  Environ Sci Pollut Res Int       Date:  2015-05-27       Impact factor: 4.223

3.  Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam.

Authors:  Jung-Woo Bae; Chang-Ik Choi; Choon-Gon Jang; Seok-Yong Lee
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

4.  Characterization and In Vitro Skin Permeation of Meloxicam-Loaded Liposomes versus Transfersomes.

Authors:  Sureewan Duangjit; Praneet Opanasopit; Theerasak Rojanarata; Tanasait Ngawhirunpat
Journal:  J Drug Deliv       Date:  2010-11-07

5.  Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers.

Authors:  Mario Del Tacca; Giuseppe Pasqualetti; Giovanni Gori; Pasquale Pepe; Antonello Di Paolo; Marianna Lastella; Ferdinando De Negri; Corrado Blandizzi
Journal:  Ther Clin Risk Manag       Date:  2013-07-24       Impact factor: 2.423

6.  Meloxicam transdermal delivery: effect of eutectic point on the rate and extent of skin permeation.

Authors:  Soliman Mohammadi-Samani; Gholamhossein Yousefi; Farhad Mohammadi; Fatemeh Ahmadi
Journal:  Iran J Basic Med Sci       Date:  2014-02       Impact factor: 2.699

7.  Enhanced transdermal delivery of meloxicam by nanocrystals: Preparation, in vitro and in vivo evaluation.

Authors:  Qin Yu; Xiying Wu; Quangang Zhu; Wei Wu; Zhongjian Chen; Ye Li; Yi Lu
Journal:  Asian J Pharm Sci       Date:  2017-12-07       Impact factor: 6.598

8.  Quantitation of meloxicam in the plasma of koalas (Phascolarctos cinereus) by improved high performance liquid chromatography.

Authors:  Benjamin Kimble; Kong Ming Li; Merran Govendir
Journal:  J Vet Sci       Date:  2013-02-05       Impact factor: 1.672

9.  Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.

Authors:  Tomoko Hasunuma; Masahiro Tohkin; Nahoko Kaniwa; In-Jin Jang; Cui Yimin; Masaru Kaneko; Yoshiro Saito; Masahiro Takeuchi; Hiroshi Watanabe; Yasushi Yamazoe; Yoshiaki Uyama; Shinichi Kawai
Journal:  Br J Clin Pharmacol       Date:  2016-03-14       Impact factor: 4.335

10.  Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.

Authors:  Rehab Abdelmonem; Menna M Abdellatif; Inas Essam Ibrahim Al-Samadi; Mohamed A El-Nabarawi
Journal:  Drug Des Devel Ther       Date:  2021-10-16       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.